CD34 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits CD34 indirectly by targeting the BCR-ABL fusion protein. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a multi-targeted kinase inhibitor that can indirectly inhibit CD34+ cells by disrupting angiogenesis and stromal support. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is primarily used to inhibit BCR-ABL kinase activity in CML, indirectly affecting CD34+ cells by targeting this oncogenic protein. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib targets the BCR-ABL fusion protein, often expressed in CD34+ cells associated with CML, indirectly inhibiting CD34+ leukemia cells. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
Ponatinib is a tyrosine kinase inhibitor effective against BCR-ABL, including the T315I mutation, indirectly inhibiting CD34+ leukemia cells by targeting this oncogenic protein. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $51.00 $112.00 | 10 | |
Midostaurin is a multi-kinase inhibitor that indirectly impacts CD34+ cells by inhibiting the proliferation of leukemic cells. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that indirectly inhibits CD34+ cells by targeting various receptors involved in angiogenesis and tumor growth. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including RAF kinases, VEGFR, and PDGFR, indirectly affecting CD34+ cells by disrupting angiogenesis and the tumor microenvironment. | ||||||
Cediranib | 288383-20-0 | sc-483599 sc-483599A sc-483599B | 5 mg 10 mg 25 mg | $137.00 $220.00 $406.00 | ||
Cediranib is a VEGFR inhibitor that indirectly impacts CD34+ cells by inhibiting angiogenesis, which is essential for the survival and growth of tumor-associated CD34+ cells. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Cabozantinib is a multi-kinase inhibitor that indirectly inhibits CD34+ cells in certain malignancies by disrupting the tumor microenvironment. | ||||||